Randomized multicenter phase II study evaluating two dosing schedules of TG4010 (MVA-MUC1-IL2) in patients with adenocarcinoma of the prostate

Trial Profile

Randomized multicenter phase II study evaluating two dosing schedules of TG4010 (MVA-MUC1-IL2) in patients with adenocarcinoma of the prostate

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2006

At a glance

  • Drugs TG 4010 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2006 Status change
    • 11 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top